NasdaqCM - Delayed Quote USD
Pulmatrix, Inc. (PULM)
At close: October 21 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
11,392.0000
7,298.0000
6,071.0000
5,169.0000
12,634.0000
--
Operating Expense
20,092.0000
22,038.0000
25,018.0000
21,759.0000
22,496.0000
--
Operating Income
-8,700.0000
-14,740.0000
-18,947.0000
-16,590.0000
-9,862.0000
--
Net Non Operating Interest Income Expense
702.0000
867.0000
309.0000
7.0000
82.0000
--
Other Income Expense
-2,845.0000
-248.0000
-198.0000
-3,588.0000
-9,528.0000
--
Pretax Income
-10,843.0000
-14,121.0000
-18,836.0000
-20,171.0000
-19,308.0000
--
Net Income Common Stockholders
-10,843.0000
-14,121.0000
-18,836.0000
-23,368.0000
-19,308.0000
--
Diluted NI Available to Com Stockholders
-10,843.0000
-14,121.0000
-18,836.0000
-23,368.0000
-19,308.0000
--
Basic EPS
-2.98
-3.87
-5.46
-8.63
-13.43
--
Diluted EPS
-2.98
-3.87
-5.46
-8.63
-13.43
--
Basic Average Shares
3,652.2880
3,651.9110
3,447.7010
2,708.5580
1,437.6660
--
Diluted Average Shares
3,652.2880
3,651.9110
3,447.7010
2,708.5580
1,437.6660
--
Total Operating Income as Reported
-11,318.0000
-14,740.0000
-18,947.0000
-20,167.0000
-9,862.0000
--
Total Expenses
20,092.0000
22,038.0000
25,018.0000
21,759.0000
22,496.0000
--
Net Income from Continuing & Discontinued Operation
-10,843.0000
-14,121.0000
-18,836.0000
-20,171.0000
-19,308.0000
--
Normalized Income
-8,225.0000
-14,121.0000
-18,836.0000
-16,594.0000
-10,019.0000
--
Interest Income
702.0000
867.0000
309.0000
7.0000
82.0000
--
Net Interest Income
702.0000
867.0000
309.0000
7.0000
82.0000
--
EBIT
-8,700.0000
-14,740.0000
-18,947.0000
-16,590.0000
-9,862.0000
--
EBITDA
-7,631.0000
-13,265.0000
-17,402.0000
-15,354.0000
-8,819.0000
--
Reconciled Depreciation
1,069.0000
1,475.0000
1,545.0000
1,236.0000
1,043.0000
--
Net Income from Continuing Operation Net Minority Interest
-10,843.0000
-14,121.0000
-18,836.0000
-20,171.0000
-19,308.0000
--
Total Unusual Items Excluding Goodwill
-2,618.0000
--
--
-3,577.0000
-9,289.0000
-7,268.0000
Total Unusual Items
-2,618.0000
--
--
-3,577.0000
-9,289.0000
-7,268.0000
Normalized EBITDA
-5,013.0000
-13,265.0000
-17,402.0000
-11,777.0000
470.0000
--
12/31/2019 - 3/21/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LVTX LAVA Therapeutics N.V.
1.7206
+3.03%
SNPX Synaptogenix, Inc.
3.6000
+11.46%
TECX Tectonic Therapeutic, Inc.
36.90
-1.34%
PHIO Phio Pharmaceuticals Corp.
3.1800
+9.28%
HLVX HilleVax, Inc.
1.8300
-2.66%
ANTX AN2 Therapeutics, Inc.
1.0800
+2.86%
ATXI Avenue Therapeutics, Inc.
2.0000
-5.21%
HSTO Histogen Inc.
0.3000
+41.18%
BLPH Bellerophon Therapeutics, Inc.
0.0360
0.00%
DOMH Dominari Holdings Inc.
1.8200
+0.55%